tolvaptan has been researched along with furosemide in 60 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (furosemide) | Trials (furosemide) | Recent Studies (post-2010) (furosemide) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 13,631 | 1,358 | 2,486 |
| Protein | Taxonomy | tolvaptan (IC50) | furosemide (IC50) |
|---|---|---|---|
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) | 3.76 | |
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Mus musculus (house mouse) | 3.76 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (13.33) | 29.6817 |
| 2010's | 39 (65.00) | 24.3611 |
| 2020's | 13 (21.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hirano, T; Mori, T; Nakamura, S; Onogawa, T; Yamamura, Y | 1 |
| Czerwiec, F; Gheorghiade, M; Kambayashi, J; Niazi, I; Orlandi, C; Ouyang, J; Zampino, M | 1 |
| Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC; Orlandi, C; Ouyang, J; Smith, WB; Zimmer, CA | 1 |
| Burnett, JC; Cook, T; Gheorghiade, M; Grinfeld, L; Konstam, MA; Maggioni, AP; Orlandi, C; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C | 1 |
| Bramer, SL; Bricmont, P; Shoaf, SE; Zimmer, CA | 1 |
| Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Laczi, F | 1 |
| Haass, M | 1 |
| Chayama, K; Kaneko, A; Kato, M; Murawaki, Y; Okada, M; Okita, K; Ono, N; Sakaida, I; Sata, M; Yoshihara, H; Yoshihara, N | 1 |
| Asanoi, H; Hori, M; Izumi, T; Matsuzaki, M; Tsutamoto, T | 1 |
| Hirayama, A; Hori, M; Inomata, T; Izumi, T; Matsuzaki, M | 1 |
| Fujiki, H; Nakamura, S; Nakayama, S; Onogawa, T; Sakamoto, Y; Yamamura, Y | 1 |
| Bilsker, M; Hauptman, PJ; Konstam, MA; O'Brien, T; Orlandi, C; Sequeira, R; Thomas, I; Udelson, JE; Zimmer, C | 1 |
| Burnett, JC; Costello-Boerrigter, LC | 1 |
| Blair, J; Burnett, JC; Gheorghiade, M; Grinfeld, L; Konstam, MA; Krasa, HB; Maggioni, AP; Ouyang, J; Pang, PS; Swedberg, K; Vaduganathan, M; Zannad, F; Zimmer, C | 1 |
| Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M | 1 |
| Hashimoto, Y; Iwatsuka, R; Matsue, Y; Matsumura, A; Mizukami, A; Nagahori, W; Ohno, M; Seya, M; Suzuki, M | 1 |
| Burnett, J; Gheorghiade, M; Grinfeld, L; Hauptman, PJ; Konstam, MA; Kostic, D; Krasa, HB; Maggioni, A; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C | 1 |
| Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Miura, K; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamazaki, T; Yoshiyama, M | 1 |
| Fujii, H; Matsue, Y; Nagahori, W; Nishioka, T; Noda, M; Okishige, K; Onishi, Y; Ono, Y; Sakurada, H; Satoh, Y; Sugi, K; Suzuki, M; Takahashi, A; Tejima, T; Torii, S; Yamaguchi, S; Yoshida, K | 1 |
| Formiga, F; Navarro, A; Poch, E; Pose, A; Runkle, I; Tejedor, A; Villabona, C | 1 |
| Formiga, F; Morales-Rull, JL; Trullàs, JC | 1 |
| Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N | 2 |
| Goto, A; Matsumoto, M; Nakamura, M; Sakaida, I; Terai, S | 1 |
| Fukuda, K; Humbert, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y | 1 |
| Imamura, T; Kinugawa, K | 1 |
| Hasegawa, T; Ikeda, U; Izawa, A; Kimura, K; Misawa, T; Momose, T; Morita, T; Motoki, H | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Gheorghiade, M; Givertz, MM; Hillege, HL; Metra, M; O'Connor, CM; Ponikowski, P; Subacius, H; Teerlink, JR; Ter Maaten, JM; Valente, MA; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Iwahasi, T; Iwahori, A; Iwasaki, T; Koizumi, N; Maruno, K; Matsuyama, K; Nishibe, T; Ogino, H; Takahashi, S; Toguchi, K | 1 |
| Momomura, SI | 1 |
| Huang, WL; Wang, HB; Xiong, XL; Yang, J; Yang, Y; Zhang, YF | 1 |
| Ako, J; Ikeda, Y; Inomata, T; Izumi, T; Kida, K; Kumagai, Y; Sato, N; Shibagaki, Y; Shinagawa, H | 1 |
| Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M | 1 |
| Akashi, YJ; Inomata, T; Izumi, T; Kida, K; Sato, N; Shibagaki, Y; Tominaga, N | 2 |
| Egashira, H; Hidaka, H; Ichita, C; Kako, M; Koizumi, K; Masuda, S; Nakayama, T; Sasaki, A; Sung, JH; Tokoro, S; Uojima, H | 1 |
| Hoshiyama, A; Kamata, Y; Masaki, T; Shichiri, M; Takada, T; Toki, T | 1 |
| Ako, J; Ikeda, Y; Inomata, T; Izumi, T; Kida, K; Sato, N; Shibagaki, Y | 1 |
| Iida, Y; Shimizu, H; Yoshitake, A | 1 |
| Akimoto, T; Imai, T; Maeshima, A; Masuda, T; Miki, A; Miyazawa, Y; Murakami, T; Muto, S; Myoga, A; Nagata, D; Nakagawa, S; Ohara, K; Okada, M; Saito, O; Sekiguchi, C; Sugase, T; Yoshizawa, H | 1 |
| Kida, Y | 1 |
| Akimoto, T; Kobayashi, T; Maeshima, A; Masuda, T; Matsuoka, R; Murakami, T; Muto, S; Nagata, D; Nagayama, I; Nakagawa, S; Ohara, K; Saito, O | 1 |
| Hirai, H; Hosono, M; Kaku, D; Kubota, Y; Nakahira, A; Sasaki, Y; Shibata, T; Suehiro, S; Suehiro, Y | 1 |
| Hidaka, H; Kako, M; Koizumi, W; Kubota, K; Nakazawa, T; Shibuya, A; Sung, JH; Tanaka, Y; Uojima, H; Wada, N | 1 |
| Ishihara, T; Isoai, A; Iwasa, M; Kato, M; Kobayashi, R; Soneda, N; Takei, Y; Torii, N | 1 |
| Aikata, H; Chayama, K; Fujino, H; Hiramatsu, A; Imamura, M; Kawaoka, T; Kodama, K; Morio, K; Murakami, E; Nakahara, T; Namba, M; Ohya, K; Tsuge, M; Uchikawa, S; Yamauchi, M | 1 |
| Cox, ZL; Hung, R; Lenihan, DJ; Testani, JM | 1 |
| Abe, H; Arai, T; Atsukawa, M; Chuma, M; Fukunishi, S; Hattori, N; Hiraoka, A; Iio, E; Ikegami, T; Itokawa, N; Iwakiri, K; Iwasa, M; Kato, K; Kondo, C; Kumada, T; Michitaka, K; Nakagawa-Iwashita, A; Nozaki, A; Okubo, H; Okubo, T; Senoh, T; Tada, T; Takaguchi, K; Takei, Y; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsutsui, A; Uojima, H; Watanabe, T; Yokohama, K; Yoshida, Y | 1 |
| Fujii, K; Kin, H; Matsumura, K; Otagaki, M; Park, H; Shiojima, I; Sugiura, T; Takahashi, H; Yamamoto, Y; Yokoi, M; Yoshioka, K | 1 |
| Elkayam, U; Fong, MW; Grazette, LP; Han, EE; Kuo, A; Lou, M; Mehra, A; Ng, TMH; Upadhyay, RY; Yoon, AJ | 1 |
| Amitani, K; Iha, H; Imura, H; Ishihara, S; Ishikawa, M; Ishizuka, A; Ito, Y; Kikuchi, A; Kobayashi, N; Maruyama, Y; Mitsuishi, T; Nakama, K; Nakamura, S; Nohara, T; Ohkuma, S; Omote, T; Sato, N; Shigihara, S; Shimizu, W; Sone, M; Takagi, K; Takahashi, N; Tokuyama, H; Yamamoto, E | 1 |
| Bricmont, P; Repella Gordon, J; Shoaf, SE | 1 |
| Bagga, A; Hari, P; Meena, J; Sinha, A | 1 |
| Fujiwara, A; Haze, T; Hirawa, N; Katsumata, M; Kawano, R; Kobayashi, Y; Komiya, S; Ohki, Y; Ozawa, M; Saka, S; Suzuki, S; Tamura, K | 1 |
| Aihara, M; Kinugawa, K; Matsukawa, M; Nakamura, Y; Sano, H | 1 |
| Kawano, M; Kurozumi, A; Nakano, M; Nishio, S; Tajima, E; Takimura, H; Takimura, Y; Taniguchi, R; Tsukahara, R; Tsuzuki, I; Yamaguchi, Y | 1 |
| Hasegawa, M; Hayashi, H; Inaguma, D; Koide, S; Ogata, S; Tagaya, T; Takahashi, K; Tsuboi, N; Yuzawa, Y | 1 |
5 review(s) available for tolvaptan and furosemide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Etiology, diagnostics and therapy of hyponatremias].
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Blood Volume; Brain Diseases; Central Nervous System; Chronic Disease; Demeclocycline; Demyelinating Diseases; Diagnosis, Differential; Diuretics; Extracellular Fluid; Furosemide; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lithium Compounds; Morpholines; Osmolar Concentration; Osmosis; Pyrroles; Severity of Illness Index; Sodium; Spiro Compounds; Time Factors; Tolvaptan; Vasopressins | 2008 |
[Vasopressin receptor antagonists and heart failure].
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Female; Follow-Up Studies; Furosemide; Heart Failure; Hormone Antagonists; Humans; Hyponatremia; Indoles; Male; Morpholines; Platelet Aggregation Inhibitors; Pyrroles; Pyrrolidines; Sodium Potassium Chloride Symporter Inhibitors; Spiro Compounds; Time Factors; Tolvaptan | 2009 |
[Alternatives to conventional diuretic therapy in heart failure].
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardio-Renal Syndrome; Clinical Trials as Topic; Dopamine; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Furosemide; Heart Failure; Hemofiltration; Humans; Multicenter Studies as Topic; Saline Solution, Hypertonic; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tolvaptan | 2014 |
Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tolvaptan | 2018 |
28 trial(s) available for tolvaptan and furosemide
| Article | Year |
|---|---|
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Chronic Disease; Diuretics; Double-Blind Method; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Osmolar Concentration; Sodium; Tolvaptan; Treatment Outcome; Urinalysis; Water-Electrolyte Balance | 2003 |
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cross-Over Studies; Diuretics; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Placebos; Potassium; Sodium; Tolvaptan; Urination; Vasopressins; Water; Water-Electrolyte Balance | 2006 |
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan | 2007 |
Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cross-Over Studies; Diuretics; Drug Interactions; Furosemide; Humans; Hydrochlorothiazide; Male; Osmolar Concentration; Renin; Sodium; Tolvaptan | 2007 |
A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Dose-Response Relationship, Drug; Edema; Female; Furosemide; Humans; Japan; Liver Cirrhosis; Lower Extremity; Male; Middle Aged; Tolvaptan; Treatment Outcome; Waist Circumference | 2010 |
Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Drug Therapy, Combination; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Potassium; Sodium; Tolvaptan; Young Adult | 2011 |
Phase III clinical pharmacology study of tolvaptan.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Body Weight; Calcium; Creatinine; Diuretics; Double-Blind Method; Drug Therapy, Combination; Edema, Cardiac; Female; Furosemide; Humans; Magnesium; Male; Middle Aged; Potassium; Sodium; Tolvaptan; Uric Acid | 2011 |
A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure, Systolic; Humans; Male; Middle Aged; Statistics as Topic; Stroke Volume; Tolvaptan; Vasopressins; Ventricular Function, Left | 2011 |
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hypotension; Male; Middle Aged; Renal Insufficiency; Sodium; Tolvaptan; Treatment Outcome | 2012 |
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
Topics: Aged; Analysis of Variance; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Diuretics; Dyspnea; Female; Furosemide; Heart Failure, Systolic; Humans; Hyponatremia; Male; Middle Aged; Proportional Hazards Models; Tolvaptan; Weight Loss | 2013 |
Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Drug Therapy, Combination; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Japan; Natriuretic Peptide, Brain; Prospective Studies; Renal Insufficiency; Research Design; Tolvaptan | 2014 |
Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Furosemide; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Tolvaptan | 2015 |
Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Blood Urea Nitrogen; Creatinine; Diuretics; Drug Interactions; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Pilot Projects; Renal Insufficiency, Chronic; Tolvaptan; Uric Acid | 2015 |
Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Renal Insufficiency; Tolvaptan | 2016 |
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Biomarkers; Decision Support Techniques; Diuresis; Diuretics; Female; Furosemide; Heart Failure; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Patient Readmission; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2016 |
Effects of short-term administration of tolvaptan after open heart surgery.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Cardiac Surgical Procedures; Diuretics; Drug Monitoring; Drug Therapy, Combination; Female; Fluid Shifts; Furosemide; Humans; Male; Middle Aged; Postoperative Complications; Spironolactone; Tolvaptan; Treatment Outcome; Urinalysis | 2016 |
Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment - Results From the K-STAR Study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Kidney Diseases; Male; Tolvaptan; Treatment Outcome | 2017 |
Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hyponatremia; Kidney Failure, Chronic; Male; Potassium; Prospective Studies; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2017 |
Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tolvaptan; Treatment Outcome | 2017 |
Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Diuretics; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Renal Elimination; Renal Insufficiency, Chronic; Sodium; Tolvaptan; Water | 2018 |
Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Biomarkers; Creatinine; Drug Resistance; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Male; Prospective Studies; Renal Insufficiency; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Treatment Outcome | 2019 |
Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Cardiopulmonary Bypass; Cardiovascular Surgical Procedures; Diuretics; Drug Monitoring; Drug Therapy, Combination; Female; Furosemide; Humans; Kidney Function Tests; Male; Middle Aged; Postoperative Complications; Spironolactone; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 2016 |
Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.
Topics: Aged; Aged, 80 and over; Ascites; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furosemide; Glomerular Filtration Rate; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Tolvaptan | 2020 |
Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.
Topics: Administration, Oral; Aged; Chlorothiazide; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Infusions, Intravenous; Male; Metolazone; Middle Aged; Prospective Studies; Retrospective Studies; Tolvaptan; Treatment Outcome | 2020 |
Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Hyponatremia; Prospective Studies; Tolvaptan | 2020 |
Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
Topics: Aged; Aged, 80 and over; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Blood Pressure; Body Weight; Drug Therapy, Combination; Echocardiography; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan | 2020 |
Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Clinical Trials as Topic; Cross-Over Studies; Drug Approval; Drug Interactions; Female; Furosemide; Guidelines as Topic; Half-Life; HEK293 Cells; Humans; Liver-Specific Organic Anion Transporter 1; Male; Neoplasm Proteins; Organic Anion Transporters, Sodium-Independent; Rosuvastatin Calcium; Tolvaptan; United States; United States Food and Drug Administration; Young Adult | 2021 |
Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium; Tolvaptan; Water-Electrolyte Imbalance | 2022 |
27 other study(ies) available for tolvaptan and furosemide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuresis; Diuretics; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Electrolytes; Furosemide; Hormones; Male; Osmolar Concentration; Random Allocation; Rats; Rats, Sprague-Dawley; Renin; Sodium; Tolvaptan; Water | 2000 |
Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Body Weight; Creatinine; Diuretics; Echocardiography; Furosemide; Heart Failure; Heart Rate; Male; Organ Size; Osmolar Concentration; Potassium; Rats; Rats, Inbred Lew; Renin; Sodium; Tolvaptan; Ventricular Remodeling | 2008 |
Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Body Weight; Chlorides; Disease Models, Animal; Diuretics; Dogs; Furosemide; Heart Failure; Kidney; Male; Potassium; Renin; Sodium; Tolvaptan | 2011 |
Controlling the flood gates: vaptans, furosemide and the quest for a renal protective diuresis.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Furosemide; Heart Failure; Heart Failure, Systolic; Humans; Kidney; Male; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2011 |
Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Furosemide; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Comparative Effectiveness Research; Creatinine; Diuresis; Diuretics; Female; Furosemide; Heart Failure; Humans; Hypernatremia; Kidney Function Tests; Male; Multivariate Analysis; Natriuretic Peptide, Brain; Prospective Studies; Renal Insufficiency; Time Factors; Tolvaptan; Urination | 2013 |
Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
Topics: Acute-Phase Reaction; Animals; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Male; Myocardial Infarction; Rats; Rats, Wistar; Tolvaptan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |
[The treament of hyponatremia secundary to the syndrome of inappropriate antidiuretic hormone secretion].
Topics: Acute Disease; Algorithms; Benzazepines; Combined Modality Therapy; Decision Support Techniques; Fluid Therapy; Furosemide; Humans; Hyponatremia; Inappropriate ADH Syndrome; Infusions, Intravenous; Saline Solution, Hypertonic; Severity of Illness Index; Tolvaptan | 2013 |
Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Furosemide; Humans; Liver Cirrhosis; Male; Spironolactone; Tolvaptan | 2015 |
Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension.
Topics: Administration, Oral; Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drug Administration Schedule; Female; Furosemide; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Outpatients; Prospective Studies; Tolvaptan; Treatment Outcome | 2015 |
Mid-Term Administration of Tolvaptan Improves Renal Function Accompanied by Dose-Reduction in Furosemide in Aquaporin-Defined Responders.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporins; Arginine Vasopressin; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Kidney Function Tests; Medication Therapy Management; Patient Selection; Tolvaptan | 2015 |
Tolvaptan, Is It a Trump to Worsening Renal Function?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Renal Insufficiency, Chronic; Tolvaptan | 2017 |
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Carcinoma, Hepatocellular; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Furosemide; Humans; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Spironolactone; Tolvaptan; Treatment Outcome | 2017 |
Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diabetic Nephropathies; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Nephrotic Syndrome; Renal Insufficiency; Severity of Illness Index; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance | 2018 |
Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Aortic Aneurysm, Thoracic; Blood Vessel Prosthesis Implantation; Drug Administration Schedule; Drug Therapy, Combination; Female; Furosemide; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Time Factors; Tolvaptan; Treatment Outcome; Urination; Water-Electrolyte Balance; Weight Loss | 2019 |
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzhydryl Compounds; Body Composition; Female; Fluid Shifts; Furosemide; Glucosides; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 2019 |
Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Female; Furosemide; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Tolvaptan; Treatment Outcome | 2019 |
Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Drug Therapy, Combination; Edema; Fluid Shifts; Furosemide; Humans; Leg; Liver Cirrhosis; Male; Renal Insufficiency, Chronic; Tolvaptan | 2019 |
Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Ascitic Fluid; Diuretics; Female; Fluid Therapy; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Product Surveillance, Postmarketing; Serum Albumin; Spironolactone; Tolvaptan | 2019 |
Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Female; Follow-Up Studies; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Muscle, Skeletal; Organ Size; Prognosis; Retreatment; Retrospective Studies; Sarcopenia; Survival Rate; Time Factors; Tolvaptan; Tomography, X-Ray Computed; Young Adult | 2020 |
Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
Topics: Adult; Aged; Aged, 80 and over; Diuretics; Drug Therapy, Combination; Edema; Female; Furosemide; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Prognosis; Retrospective Studies; ROC Curve; Spironolactone; Survival Rate; Time Factors; Tolvaptan | 2020 |
Renoprotective effect of tolvaptan in patients with new-onset acute heart failure.
Topics: Diuretics; Furosemide; Heart Failure; Humans; Retrospective Studies; Tolvaptan | 2020 |
Efficacy and Safety of Combination Therapy with Tolvaptan and Furosemide in Children with Nephrotic Syndrome and Refractory Edema: A Prospective Interventional Study.
Topics: Child; Child, Preschool; Diuretics; Drug Therapy, Combination; Edema; Furosemide; Heart Failure; Humans; Male; Nephrotic Syndrome; Prospective Studies; Tolvaptan | 2022 |
Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Furosemide; Heart Failure; Hospital Mortality; Humans; Japan; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2023 |
Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.
Topics: Diuretics; Furosemide; Heart Failure; Humans; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2023 |
Tolvaptan's Association with Low Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease and Acute Decompensated Heart Failure.
Topics: Acute Disease; Acute Kidney Injury; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Furosemide; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2023 |